X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/08/2859062/0/en/Samsung-Bioepis-Releases-Second-Quarter-2024-US-Biosimilar-Market-Report.html
https://www.globenewswire.com/news-release/2024/04/05/2858286/0/en/Samsung-Bioepis-Initiates-Phase-3-Clinical-Trial-for-SB27-Proposed-Biosimilar-to-Keytruda-Pembrolizumab.html
https://www.globenewswire.com/news-release/2024/03/09/2843392/0/en/Samsung-Bioepis-Presents-Two-Abstracts-for-Its-Immunology-Portfolio-at-the-2024-American-Academy-of-Dermatology-AAD-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/01/17/2810449/0/en/Samsung-Bioepis-Releases-First-Quarter-2024-US-Biosimilar-Market-Report.html
https://www.globenewswire.com//news-release/2023/11/30/2788227/0/en/Samsung-Bioepis-Secures-US-License-Date-for-SB17-a-Proposed-Biosimilar-to-Stelara.html
https://www.fiercepharma.com/pharma/jj-settlement-samsung-and-sandoz-lock-down-stelara-biosimilar-license
https://www.globenewswire.com//news-release/2023/11/07/2775667/0/en/Samsung-Bioepis-Organon-Announce-FDA-Acceptance-of-Supplemental-Biologics-License-Application-sBLA-for-Interchangeability-Designation-for-HADLIMA-adalimumab-bwwd-a-Biosimilar-to-Hu.html
https://www.globenewswire.com//news-release/2023/10/15/2760267/0/en/Samsung-Bioepis-Presents-Phase-1-and-3-Clinical-Results-for-SB16-a-Proposed-Biosimilar-to-Prolia%E2%81%B1-denosumab-at-ASBMR-2023.html
https://www.globenewswire.com//news-release/2023/10/11/2758056/0/en/Samsung-Bioepis-Presents-Two-Abstracts-at-EADV-2023-Congress-Highlighting-Continuous-Dedication-in-Dermatology.html
https://www.globenewswire.com/news-release/2023/10/07/2756354/0/en/Samsung-Bioepis-Presents-Post-hoc-Analysis-of-Phase-3-Clinical-Trial-for-SB15-a-Proposed-Biosimilar-to-Eylea%E2%81%B1-Aflibercept-at-EURETINA-2023.html
Market Place
Share 
